Case Report: Reversal of Integrase Inhibitor– and Tenofovir Alafenamide–Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF
Year: 2021
Type: article
Study design: Case Report
Abstract: We report a case of substantial weight gain in a virologically suppressed patient with HIV after changing his antiretroviral therapy from efavirenz/emtricitabine/tenofovir DF to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide with subsequent rapid weight loss upon switching back. The role of antiretrovirals in weight gain and loss and patient- and HIV-specific factors are discussed.
Source: Open Forum Infectious Diseases
DOI: 10.1093/ofid/ofab403
Authors: F Will Pohlman, Kara S McGee, Mehri S McKellar
Institutions: Duke University, Duke Medical Center
Language: English
Subfield: Emergency Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,465
OpenAlex ID: W3189669291